BACKGROUND: Severe @entity339 ( @entity339 ) >= 3+ and left @entity67 in @entity712 @entity1 are markers of CRT non response. The MitraClip (MC) implantation is a therapy for @entity339 >= 3+ in @entity1 with high surgical risk of mitral valve reconstruction. METHODS AND RESULTS: We investigated 42 @entity1 with CRT and @entity339 >= 3+ who received an MC device at our center. One and two year mortality rates were compared with the predicted mortality by Seattle @entity712 Model (SHFM) and meta-analysis global group in chronic @entity712 (MAGGIC), using the baseline characteristics of @entity1 at the time of MC implantation. The median time interval between CRT and MC implantation was 20.1 (4.5-43.3) months. In 19 @entity1 we observed a functional regurgitation with normal leaflets and in 23 @entity1 a degenerative mechanism for @entity339 . There was no change in mean QRS duration by biventricular pacing or MC implantation. The use of MC led to significant reductions in: median N-terminal pro-brain natriuretic peptide (NT-proBNP) level (pg/ml) from 3923 to 2636 (p=0.02), @entity997 pressure gradient (TRPG) from 43 to 35mmHg (p=0.019) and in left ventricular end-diastolic volume (LVEDV) by MC (p=0.008). At the 2year follow-up interval the all-cause mortality was 25%. CONCLUSION: MC implantation leads to an improvement of NT-proBNP level, TRPG and LVEDV in both functional and degenerative @entity339 but does not influence QRS duration. Two year all-cause mortality was 25% and did not differ significantly from that predicted by SHFM and MAGGIC.

MitraClip in CRT non-responders with severe XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['Heart Failure', 'heart failure'] @entity339 :: ('MESH:D008944', 'Disease') :: ['MR', 'mitral regurgitation'] @entity997 :: ('MESH:D014262', 'Disease') :: ['tricuspid regurgitation'] @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular dyssynchrony']
@entity339 :: (MESH:D008944,Disease) :: ['mitral regurgitation']
